Description
Book SynopsisMetal-based anticancer drugs are among the most successful therapeutic agents, as evidenced by the frequent prescription of selected platinum and arsenic compounds to patients. Metal-based Anticancer Agents covers the interdisciplinary world of inorganic drug discovery and development by introducing the most prominent compound classes based on different transition metals, discussing emerging concepts and enabling methods, as well as presenting key pre-clinical and clinical aspects. Recent progress on the unique features of next-generation targeted metal-based anticancer agents, including supramolecular coordination complexes used for both therapy and drug delivery, promise a bright future beyond the benefits of pure cytotoxic activity. With contributions from global leaders in the field, this book will serve as a useful reference to established researchers as well as a practical guide to those new to metallodrugs, and postgraduate students of medicinal chemistry and metallobiology.
Table of ContentsEnhancing the Therapeutic Potential of Platinum-Based Anti-Cancer Agents by Incorporating Clinically Approved Drugs as Ligands; Ruthenium, Osmium and Iridium in the Fight Against Cancer; Iron Compounds as Anticancer Agents; Recent Advances in Anticancer Copper Compounds; Anticancer Gold Compounds; Heterometallic Complexes as Anticancer Agents; Vanadium Compounds as Enzyme Inhibitors with a Focus on Anticancer Effects; Arsenic-based Anticancer Agents; Supramolecular Metal-based Structures for Applications in Cancer Therapy; Enabling Methods to Elucidate the Effects of Metal-based Anticancer Agents; Metal-Based Radiotherapeutics; Challenges and Chances in the Pre-clinical to Clinical Translation of Anticancer Metallodrugs
